rev man export for pico 9_dob_adverse events

Review information

Authors

[Empty name][1]

[1][Empty affiliation]

Citation example: [Empty name]. rev man export for pico 9_dob_adverse events. Cochrane Database of Systematic Reviews [Year], Issue [Issue].

Characteristics of studies

Characteristics of included studies

Petrakis 2004

Methods	
Participants	
Interventions	
Outcomes	
Notes	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Uncleat how the randomization was conducted
Allocation concealment (selection bias)	Unclear risk	Not stated

Blinding of participants and personnel (performance bias)	Low risk	Following completion of these baseline assessments, subjects were randomized in a double-blind fashion to receive either naltrexone 50 mg or placebo once per day for 12 weeks.
Blinding of outcome assessment (detection bias)	Unclear risk	Not stated
Incomplete outcome data (attrition bias)	Low risk	
Selective reporting (reporting bias)	Low risk	
Other bias	Low risk	

Petrakis 2005

Methods	
Participants	
Interventions	
Outcomes	
Notes	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not stated
Allocation concealment (selection bias)	High risk	Medication was clearly labeled naltraxon
Blinding of participants and personnel (performance bias)	Unclear risk	Not stated
Blinding of outcome assessment (detection bias)	Unclear risk	Not stated
Incomplete outcome data (attrition bias)	Low risk	
Selective reporting (reporting bias)	Low risk	
Other bias	Low risk	

Petrakis 2005a

Methods	
Participants	
Interventions	
Outcomes	
Notes	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not stated
Allocation concealment (selection bias)	High risk	Medication was clearly labeled naltraxon
Blinding of participants and personnel (performance bias)	Unclear risk	Not stated
Blinding of outcome assessment (detection bias)	Unclear risk	Not stated
Incomplete outcome data (attrition bias)	Low risk	
Selective reporting (reporting bias)	Low risk	
Other bias	Low risk	

Witte 2012

Methods	
Participants	
Interventions	
Outcomes	
Notes	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	-
Allocation concealment (selection bias)	Unclear risk	-
Blinding of participants and personnel (performance bias)	Unclear risk	-
Blinding of outcome assessment (detection bias)	Unclear risk	Not stated
Incomplete outcome data (attrition bias)	Low risk	
Selective reporting (reporting bias)	Low risk	
Other bias	Low risk	

Footnotes

Characteristics of excluded studies

Footnotes

Characteristics of studies awaiting classification

Footnotes

Characteristics of ongoing studies

Footnotes

References to studies

Included studies

Petrakis 2004

[Empty]

Petrakis 2005

[Empty]

Petrakis 2005a

[Empty]

Witte 2012

[Empty]

Excluded studies

Data and analyses

1 Anticraving vs placebo

Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate
1.1 Nausea	4	308	Risk Ratio (M-H, Random, 95% CI)	1.32 [1.09, 1.61]
1.2 Headache	2	54	Risk Ratio (M-H, Random, 95% CI)	1.31 [0.69, 2.49]
1.3 Weakness	1	31	Risk Ratio (M-H, Random, 95% CI)	21.65 [1.39, 337.90]
1.4 Diarrhea	2	54	Risk Ratio (M-H, Random, 95% CI)	1.55 [0.20, 11.99]
1.5 Restlessness	3	285	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.79, 1.27]

1.6 Sleep disturbances	2	54	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.52, 2.14]
1.7 Allergic reactions (severe)	1	31	Risk Ratio (M-H, Random, 95% CI)	1.88 [0.57, 6.19]
1.8 Abdominal pain	2	254	Risk Ratio (M-H, Random, 95% CI)	1.41 [1.09, 1.83]
1.9 Vomiting	2	254	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.83, 1.74]
1.10 Nervousness	2	254	Risk Ratio (M-H, Random, 95% CI)	1.13 [0.93, 1.37]

Figures

Figure 1 (Analysis 1.1)



Forest plot of comparison: 1 Anticraving vs placebo, outcome: 1.1 Nausea.

Figure 2 (Analysis 1.2)



Forest plot of comparison: 1 Anticraving vs placebo, outcome: 1.2 Headache.

Figure 3 (Analysis 1.4)



Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias

Forest plot of comparison: 1 Anticraving vs placebo, outcome: 1.4 Diarrhea.

Figure 4 (Analysis 1.6)



Risk of bias legend
(**A**) Random sequence generation (selection bias)
(**B**) Allocation concealment (selection bias)
(**C**) Blinding of participants and personnel (performance bias)
(**D**) Blinding of outcome assessment (detection bias)
(**E**) Incomplete outcome data (attrition bias)
(**F**) Selective reporting (reporting bias)
(**G**) Other bias

Forest plot of comparison: 1 Anticraving vs placebo, outcome: 1.6 Sleep disturbances.

Figure 5 (Analysis 1.9)



Forest plot of comparison: 1 Anticraving vs placebo, outcome: 1.9 Vomiting.

Figure 6 (Analysis 1.10)



Forest plot of comparison: 1 Anticraving vs placebo, outcome: 1.10 Nervousness.

Figure 7



Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Figure 8 (Analysis 1.8)

Study or Subgroup	Experimental Events	Experimental Total	Control Events	Control Total	Weight	Risk Ratio M-H, Random, 95% CI
Petrakis 2005	28	59	25	64	39.7%	1.21 [0.81, 1.83]
Petrakis 2005a	43	65	28	66	60.3%	1.56 [1.12, 2.17]
Total (95% CI)		**124**		**130**	**100.0%**	**1.41 [1.09, 1.83]**
Total events	71		53			

Heterogeneity: Tau² = 0.00; Chi² = 0.87, df = 1 (P = 0.35); I² = 0%
Test for overall effect: Z = 2.64 (P = 0.008)



Forest plot of comparison: 1 Anticraving vs placebo, outcome: 1.8 Abdominal pain.

Figure 9 (Analysis 1.5)

Study or Subgroup	Experimental Events	Experimental Total	Control Events	Control Total	Weight	Risk Ratio M-H, Random, 95% CI
Petrakis 2004	10	16	12	15	17.5%	0.78 [0.50, 1.23]
Petrakis 2005	57	59	52	64	42.8%	1.19 [1.05, 1.35]
Petrakis 2005a	51	65	56	66	39.7%	0.92 [0.79, 1.09]
Total (95% CI)		**140**		**145**	**100.0%**	**1.00 [0.79, 1.27]**
Total events	118		120			

Heterogeneity: Tau² = 0.03; Chi² = 8.25, df = 2 (P = 0.02); I² = 76%
Test for overall effect: Z = 0.00 (P = 1.00)



Forest plot of comparison: 1 Anticraving vs placebo, outcome: 1.5 Restlessness.

Figure 10 (Analysis 1.7)



Forest plot of comparison: 1 Anticraving vs placebo, outcome: 1.7 Allergic reactions (severe).